» Articles » PMID: 34149436

Primaquine Diphosphate, a Known Antimalarial Drug, Blocks Vascular Leakage Acting Through Junction Stabilization

Overview
Journal Front Pharmacol
Date 2021 Jun 21
PMID 34149436
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Endothelial barrier integrity is important for vascular homeostasis, and hyperpermeability participates in the progression of many pathological states, such as diabetic retinopathy, ischemic stroke, chronic bowel disease, and inflammatory disease. Here, using drug repositioning, we discovered that primaquine diphosphate (PD), previously known as an antimalarial drug, was a potential blocker of vascular leakage. PD inhibited the linear pattern of vascular endothelial growth factors (VEGF)-induced disruption at the cell boundaries, blocked the formation of VEGF-induced actin stress fibers, and stabilized the cortactin actin rings in endothelial cells. PD significantly reduced leakage in the Miles assay and mouse model of streptozotocin (STZ)-induced diabetic retinopathy. Targeted prediction programs and deubiquitinating enzyme activity assays identified a potential mechanism of action for PD and demonstrated that this operates via ubiquitin specific protease 1 (USP1). USP1 inhibition demonstrated a conserved barrier function by inhibiting VEGF-induced leakage in endothelial permeability assays. Taken together, these findings suggest that PD could be used as a novel drug for vascular leakage by maintaining endothelial integrity.

Citing Articles

Roles of ubiquitin-specific proteases in inflammatory diseases.

Chen R, Zhang H, Li L, Li J, Xie J, Weng J Front Immunol. 2024; 15:1258740.

PMID: 38322269 PMC: 10844489. DOI: 10.3389/fimmu.2024.1258740.


Spotlights on ubiquitin-specific protease 12 (USP12) in diseases: from multifaceted roles to pathophysiological mechanisms.

Niu K, Shi Y, Lv Q, Wang Y, Chen J, Zhang W J Transl Med. 2023; 21(1):665.

PMID: 37752518 PMC: 10521459. DOI: 10.1186/s12967-023-04540-6.


Ubiquitin-Specific Proteases (USPs) and Metabolic Disorders.

Kitamura H Int J Mol Sci. 2023; 24(4).

PMID: 36834633 PMC: 9966627. DOI: 10.3390/ijms24043219.


Diabetic retinopathy: Involved cells, biomarkers, and treatments.

Ren J, Zhang S, Pan Y, Jin M, Li J, Luo Y Front Pharmacol. 2022; 13:953691.

PMID: 36016568 PMC: 9396039. DOI: 10.3389/fphar.2022.953691.

References
1.
Gadomski S, Singh S, Singh S, Sarkar T, Klarmann K, Berenschot M . Id1 and Id3 Maintain Steady-State Hematopoiesis by Promoting Sinusoidal Endothelial Cell Survival and Regeneration. Cell Rep. 2020; 31(4):107572. PMC: 8459380. DOI: 10.1016/j.celrep.2020.107572. View

2.
Apte R, Chen D, Ferrara N . VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019; 176(6):1248-1264. PMC: 6410740. DOI: 10.1016/j.cell.2019.01.021. View

3.
Bijman M, van Nieuw Amerongen G, Laurens N, van Hinsbergh V, Boven E . Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther. 2006; 5(9):2348-57. DOI: 10.1158/1535-7163.MCT-06-0242. View

4.
Vale N, Aguiar L, Gomes P . Antimicrobial peptides: a new class of antimalarial drugs?. Front Pharmacol. 2015; 5:275. PMC: 4271771. DOI: 10.3389/fphar.2014.00275. View

5.
Ashley E, Recht J, White N . Primaquine: the risks and the benefits. Malar J. 2014; 13:418. PMC: 4230503. DOI: 10.1186/1475-2875-13-418. View